Results 11 to 20 of about 8,132 (145)

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy. [PDF]

Adv Sci (Weinh)
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Pan Y, Liu X, Meng QF, Cao L, Li R, Xu Y, Zhang J, Zhao C, Rao L, Yu C.   +9 more
europepmc   +2 more sources

Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies. [PDF]

Smart Mol
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Zhou R, Jing L, Zhang J, Guo C, Yang Q.
europepmc   +2 more sources

Non-Hematopoietic and Hematopoietic SIRPα Signaling Differently Regulates Murine B Cell Maturation in Bone Marrow and Spleen. [PDF]

PLoS ONE, 2015
B lymphocyte development occurs in the bone marrow, while final differentiation and maturation can occur in both the bone marrow and the spleen. Here we provide evidence that signal regulatory protein α (SIRPα), an Ig-superfamily ITIM-receptor expressed ...
Shrikant Shantilal Kolan, Kristina Lejon, Cecilia Koskinen Holm, Rima Sulniute, Pernilla Lundberg, Takashi Matozaki, Per-Arne Oldenborg   +6 more
doaj   +1 more source

Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma

Zhongliu Fangzhi Yanjiu, 2021
CD47 is a member of the immunoglobulin superfamily. It is expressed on various cells and tissues of human, but it is more expressed on tumor cells, especially in various hematopoietic tumors.
LUO Yiyang, FENG Xiaoli
doaj   +1 more source

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

Journal of Hematology & Oncology, 2021
Background Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signal ...
Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast, Andreas Humpe, Irmela Jeremias, Marion Subklewe, Nadja C. Fenn, Karl-Peter Hopfner   +14 more
doaj   +1 more source

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

OncoImmunology, 2018
Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling.
Peter E. van Bommel, Yuan He, Ilona Schepel, Mark A. J. M. Hendriks, Valerie R. Wiersma, Robert J. van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F. Samplonius, Wijnand Helfrich, Edwin Bremer   +11 more
doaj   +1 more source

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Journal for ImmunoTherapy of Cancer, 2023
Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers.
Timo K van den Berg, Hugo Olsman, Hanke L Matlung, Katka Franke, Imke Lodewijks, Lilian Driessen-Engels, Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter   +32 more
doaj   +1 more source

Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.

PLoS ONE, 2013
BackgroundRecent studies show the importance of interactions between CD47 expressed on acute myeloid leukemia (AML) cells and the inhibitory immunoreceptor, signal regulatory protein-alpha (SIRPα) on macrophages.
Mahban Irandoust, Julian Alvarez Zarate, Isabelle Hubeek, Ellen M van Beek, Karin Schornagel, Aart J F Broekhuizen, Mercan Akyuz, Arjan A van de Loosdrecht, Ruud Delwel, Peter J Valk, Edwin Sonneveld, Pamela Kearns, Ursula Creutzig, Dirk Reinhardt, Eveline S J M de Bont, Eva A Coenen, Marry M van den Heuvel-Eibrink, C Michel Zwaan, Gertjan J L Kaspers, Jacqueline Cloos, Timo K van den Berg   +20 more
doaj   +1 more source

Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

Journal for ImmunoTherapy of Cancer, 2022
Background The CD47-SIRPα pathway acts as an important myeloid cell immune checkpoint and targeting the CD47/SIRPα axis represents a promising strategy to promote antitumor immunity.
Juan Chen, Gang Chen, Na Li, Yao Chen, Lei Nie, Zhen-Hua Wu, Xiao-Feng Mei, Xiao-Ze Wang, Ting-Ting Guo, Mei-Zhu Jiang, Ji-Teng Wang, Hai-Bin Wang   +11 more
doaj   +1 more source

Modulation of Signal Regulatory Protein α (SIRPα) by Plasmodium Antigenic Extract: A Preliminary In Vitro Study on Peripheral Blood Mononuclear Cells

Microorganisms, 2022
Signal regulatory protein α (SIRPα) is an immunoreceptor expressed in myeloid innate immune cells that signals for inhibition of both phagocytosis and inflammatory response.
Priscilla da Costa Martins, Hugo Amorim dos Santos de Souza, Carolina Moreira Blanco, Luana Santos-de-Oliveira, Lilian Rose Pratt-Riccio, Cláudio Tadeu Daniel-Ribeiro, Paulo Renato Rivas Totino   +6 more
doaj   +1 more source